69032 Federal Register / Vol. 65, No. 221 / Wednesday, November 15, 2000 / Notices

Committee. However, collection of

follow information also involves third

party individuals (next-of-kin decedents

and physicians). This information is

necessary for the interpretation and

analysis of clinical findings and

outcomes to ascertain the relationship

between mortality and morbidity in the

clinical study cohort. The information

collected will be used by the public and

private sector for public health

planning, medical education, other

epidemiologic studies, and biomedical

research. Frequency of Response: OneTime. Affected Public: Individuals or

families; Businesses or other for profit;

not-for-profit institutions. Type of

Respondents: third party respondents

(next-of-kin decedents and physicians).

The annual reporting burden is as

follows: Estimated Number of

Respondents: 480. Estimated Number of

Responses per Respondent: 1. Average

Burden Hours Per Response are shown

in the table below; and Estimated Total

Annual Burden Hours Requested: 160.

The annualized cost to respondents is

estimated at: $3,600.

Estimates of the annual reporting

burden to respondents.

Type of respondents

Estimated

number of

respondents

×

Estimated

number of

responses per

respondent

×

Average burden

hours per

response

=

Estimated total

annual burden

hours requested

Morbidity and Mortality AFU 3rd party next-of-kin decedents .. 240 1 0.33 80

Morbidity and Mortality AFU 3rd party Physicians ................... 240 1 0.33 80

Total ............................................................................... 480 ........................ ........................ 160

Note.—There are no Capital Costs, Operating Costs or Maintenance Cost for this study.

REQUEST FOR COMMENTS: Written

comments and/or suggestions from the

public and affected agencies should

address one or more of the following

points: (1) Evaluate whether the

proposed collection of information is

necessary for the proper performance of

the function of the agency, including

whether the information will have

practical utility; (2) evaluate the

accuracy of the agency’s estimate of the

burden of the proposed collection of

information, including the validity of

the methodology and assumptions used;

(3) Enhance the quality, utility, and

clarity of the information to be

collected; and (4) Minimize the burden

of the collection of information on those

who are to respond, including the use

of appropriate automated, electronic,

mechanical, or other technological

collection techniques or other forms of

information technology.

FOR FURTHER INFORMATION: To request

more information on the proposed

project or to obtain a copy of the data

collection plans and instruments,

contact: Cheryl Nelson, Jackson Heart

Study Project Officer, 6701 Rockledge

Drive, Room 8152, MSC 7934, Rockville,

MD 20892–7934, or call non-toll-free

number (301) 435–0451 or E-mail your

request, including your address to:

cn80n@.nih.gov

COMMENTS DUE DATE: Comments

regarding this information collection are

best assured of having their full effect if

received on or before January 16, 2001.

Dated: October 20, 2000.

Peter Savage,

Acting Director, Division of Epidemiology and

Clinical Applications, National Heart, Lung,

and Blood Institute.

[FR Doc. 00–29132 Filed 11–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institute of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel,

Development of Novel Imaging Technologies.

Date: December 6–7, 2000.

Time: 8:00 am to 5:00 pm.

Agenda: To review and evaluate grant

applications.

Place: Hilton Gaithersburg, 620 Perry

Parkway, Gaithersburg, MD 20877.

Contact Person: Timothy C. Meeker, MD,

Scientific Review Administrator, Special

Referral and Resources Branch, Division of

Extramural Activities, National Cancer

Institute, 6116 Executive Boulevard, Room

8088, Rockville, MD 20852, 301/594–1279.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: November 3, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–29138 Filed 11–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.